Bacterial Armory: Engineering Dual Photosensitized Bacteria for a Triple‐Modal Therapy on Tumors

Why It Matters

The platform merges three therapeutic modalities into a single, controllable bacterial vector, offering potent tumor eradication with reduced systemic toxicity—a breakthrough for precision oncology.

Key Takeaways

• Engineered E. coli coated with polydopamine and BOD-QAS.
• Dual-laser (808 nm, 660 nm) triggers heat and ROS.
• Achieves 89.8% tumor volume reduction in mice.
• Enables fluorescence imaging for precise treatment monitoring.
• Extends bacterial colonization while regulating growth for safety.

Pulse Analysis

Bacterial carriers have long intrigued oncologists for their innate ability to home to hypoxic tumor niches, yet conventional strains often fall short on potency and safety. By integrating polydopamine—a biocompatible polymer known for strong photothermal conversion—researchers fortified the bacterial membrane, improving both structural integrity and immune‑stimulating capacity. The addition of a cationic BODIPY photosensitizer introduces a photodynamic arm, generating singlet oxygen under 660 nm illumination. This dual‑photosensitization creates a synergistic assault: heat disrupts tumor vasculature while ROS induces apoptosis, amplifying therapeutic depth beyond single‑modality approaches.

The E@PB system leverages a two‑stage “green‑to‑red” light protocol, first employing an 808 nm laser to activate the polydopamine coating for hyperthermia, then a 660 nm source to trigger the BODIPY photosensitizer. This sequential activation grants clinicians spatiotemporal control, limiting off‑target effects and allowing real‑time fluorescence imaging of bacterial distribution. Rapid accumulation within eight hours and prolonged retention at tumor sites ensure sustained therapeutic pressure, while the photosensitizer shell curtails unchecked bacterial proliferation, addressing a key biosafety concern.

Clinically, the near‑90 % tumor shrinkage observed in pre‑clinical models signals a compelling efficacy signal that could translate into reduced dosing regimens and fewer adverse events for patients. The platform’s modular design permits swapping of photosensitizers or bacterial strains, opening pathways for personalized regimens targeting diverse malignancies. As regulatory frameworks evolve for live‑biologic therapeutics, E@PB exemplifies how engineered microbes can be harnessed safely, delivering multimodal, image‑guided cancer therapy that aligns with the precision medicine paradigm.